Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes
- PMID: 40430206
- PMCID: PMC12112768
- DOI: 10.3390/life15050779
Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes
Abstract
Liver cirrhosis continues to be a major global health issue, contributing to high morbidity and mortality due to its progressive nature and associated complications. This review explores recent advancements in the diagnosis and treatment of liver cirrhosis and its related syndromes. Non-invasive diagnostic tools, such as elastography and serum biomarkers, have significantly improved early detection, reducing the need for liver biopsies. Advanced imaging techniques, including MRI and CT, further enhance diagnostic accuracy. In parallel, molecular and genomic research is providing new insights into the pathogenesis of the disease, paving the way for precision medicine. On the treatment front, pharmacological innovations, such as antifibrotic agents and targeted therapies, show promise in slowing disease progression. Endoscopic interventions like variceal banding are improving the management of complications, while advancements in liver transplantation and artificial liver support systems offer life-saving alternatives. Regenerative medicine, particularly stem cell therapy and tissue engineering, is emerging as a promising strategy for liver repair. Managing cirrhosis-related syndromes, including portal hypertension, ascites, hepatic encephalopathy, and hepatorenal syndrome, now involves evolving therapeutic approaches such as transjugular intrahepatic portosystemic shunt (TIPS) and novel pharmacotherapies. Prognostic scoring systems like the MELD and Child-Pugh are being refined with new biomarkers for better risk stratification. The future of cirrhosis care will likely involve the integration of artificial intelligence and machine learning for early diagnosis and personalized treatments, alongside emerging therapies currently under investigation. Despite these advancements, challenges such as costs, accessibility, and healthcare disparities remain barriers to widespread adoption. This review highlights the importance of incorporating innovative diagnostic and therapeutic strategies into clinical practice to improve the outcomes for patients with liver cirrhosis and its complications.
Keywords: innovative diagnostics; liver cirrhosis; prognostic scoring; regenerative medicine; targeted therapies.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.Hepatogastroenterology. 2003 Nov-Dec;50(54):1753-5. Hepatogastroenterology. 2003. PMID: 14696397
-
Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.World J Gastroenterol. 2020 Oct 7;26(37):5561-5596. doi: 10.3748/wjg.v26.i37.5561. World J Gastroenterol. 2020. PMID: 33088154 Free PMC article. Review.
-
Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.Gut. 2019 Jul;68(7):1297-1310. doi: 10.1136/gutjnl-2018-317057. Epub 2018 Nov 10. Gut. 2019. PMID: 30415233
-
Correlation between serum markers and transjugular intrahepatic portosystemic shunt prognosis in patients with cirrhotic ascites.World J Gastrointest Surg. 2024 Feb 27;16(2):481-490. doi: 10.4240/wjgs.v16.i2.481. World J Gastrointest Surg. 2024. PMID: 38463353 Free PMC article.
-
Where does TIPS fit in the management of patients with cirrhosis?JHEP Rep. 2020 May 23;2(4):100122. doi: 10.1016/j.jhepr.2020.100122. eCollection 2020 Aug. JHEP Rep. 2020. PMID: 32671331 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources